An Open-Label, Phase Ib Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in the Patients With Complete Resectable Stage III and Stage IV (M1a) Melanoma
Latest Information Update: 31 Oct 2022
At a glance
- Drugs OrienX 010 (Primary) ; Toripalimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2021 Previously reported Treprizumab term replaced with Toripalimab . Timeframe of primary endpoints measure changed.